International journal of cardiology · 2025
TELOS-plus identifies normotensive patients with pulmonary embolism at high risk of 30-day mortality.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vanni Simone, Pelagatti Lorenzo, Caviglioli Cosimo, Fabiani Ginevra, Caldi Francesca, Pellegrino Alessio, Ottaviani Maddalena, Innocenti Francesca, Nazerian Peiman
Аннотация
BACKGROUND: Risk stratification of normotensive patients with acute pulmonary embolism (PE) remains suboptimal, with current models failing to consistently identify a subset at sufficiently high risk to warrant advanced therapies. We aimed to enhance the TELOS score by integrating respiratory parameters and a refined definition of right ventricular dysfunction (RVD).
METHODS: This retrospective cohort study included 1091 normotensive PE patients from a prospective registry (2008-2019). We enhanced the TELOS score into TELOS-plus score by combining novel parameters: Multivariable logistic regression identified independent predictors of 30-day PE-related mortality. The model's performance was compared to TELOS and other established scores using ROC analysis.
RESULTS: The 30-day PE-related mortality rate was 3.8 %. Severe respiratory failure (12.8 % of patients) was associated with 15.7 % mortality (OR 8.7; 95 % CI 4.6-16.4), while revised RVD (17.8 % of patients) had a mortality of 10.3 % (OR 2.2; 95 % CI 1.1-5.1). TELOS-plus showed the highest AUC (0.85) among other bedside models except SHIeLD and identified a large intermediate-high risk group (17.1 %) with high mortality (16.1 %).
CONCLUSIONS: The TELOS-plus score reliably identifies normotensive PE patients at intermediate-high risk for 30-day mortality, with improved prognostic accuracy compared to previous models. Its simplicity and clinical applicability support its potential use in guiding decisions on escalated therapies.
METHODS: This retrospective cohort study included 1091 normotensive PE patients from a prospective registry (2008-2019). We enhanced the TELOS score into TELOS-plus score by combining novel parameters: Multivariable logistic regression identified independent predictors of 30-day PE-related mortality. The model's performance was compared to TELOS and other established scores using ROC analysis.
RESULTS: The 30-day PE-related mortality rate was 3.8 %. Severe respiratory failure (12.8 % of patients) was associated with 15.7 % mortality (OR 8.7; 95 % CI 4.6-16.4), while revised RVD (17.8 % of patients) had a mortality of 10.3 % (OR 2.2; 95 % CI 1.1-5.1). TELOS-plus showed the highest AUC (0.85) among other bedside models except SHIeLD and identified a large intermediate-high risk group (17.1 %) with high mortality (16.1 %).
CONCLUSIONS: The TELOS-plus score reliably identifies normotensive PE patients at intermediate-high risk for 30-day mortality, with improved prognostic accuracy compared to previous models. Its simplicity and clinical applicability support its potential use in guiding decisions on escalated therapies.